CDKN2A P48L

CI-VAR-00003355Explore in graph →CIViC 3377

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Unmapped disease1unmapped disease
CDKN2A P48L	(functional)	Functional	D	Supports Loss Of Function	3	submitted	EID9413 Cancer-associated mutations in p16 (CDKN2A) were assessed for their ability to bind cyclin-dependent kinases, inhibit kinase activity, and induce cell-cycle arrest in G1 phase. While P48L had levels o… (full text at CIViC) PMID 10491434 · Yarbrough et al., 1999 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.